Nuvation Bio Inc. (NUVB)$4.72
Market Cap: 808.41 MCurrency: USD
Research Snapshot
Static fundamentals, valuation context, and investor signals for Nuvation Bio Inc. (NUVB).
HEALTHCARE
BIOTECHNOLOGY
DCF ready
Valuation
-4.0x
EV/FCF, N/A FCF yield
Quality
-58.0%
ROIC, -275.7% FCF margin
Growth
N/A
5Y sales (revenue) CAGR
Balance sheet
0.2x
Debt/equity, 7.0x current ratio
Superinvestors
2
Top: David Abrams (0.1%)
Strengths to research
- Debt/equity looks manageable at 0.2x.
Watchouts
- Free cash flow margin is negative at -275.7%.
Annual data: 6 periods
Quarterly data: 24 periods
Stock snapshot: May 25, 2026
Static dataset: May 25, 2026
Quality Scorecard
Build-time composite score for NUVB.
Grade F
1
/ 100
Peer Comparison
Target stock against 8 market-cap comparable peers.
Heat map: red worst to green best
| NUVB Target | Nuvation Bio Inc. | $808.4M | -7.9x | -4.0x | -58.0% | N/A | -275.7% | N/A | N/A | N/A |
| RCKT | Rocket Pharmaceuticals Inc. | $838.3M | -1.5x | -4.0x | -80.5% | N/A | N/A | N/A | N/A | N/A |
| TRVI | Trevi Therapeutics Inc. | $667.1M | -44.2x | -15.4x | -23.3% | N/A | N/A | N/A | N/A | N/A |
| PHVS | Pharvaris NV | $1.0B | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| MESO | Mesoblast Ltd Spon ADR | $1.4B | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| PGEN | Precigen Inc. | $448.7M | -3.1x | -5.7x | -219.7% | -21.3% | -927.6% | N/A | N/A | N/A |
| ADPT | Adaptive Biotechnologies Corp. | $1.5B | -35.6x | -29.7x | -27.2% | 23.0% | -17.7% | N/A | N/A | N/A |
| ORIC | ORIC Pharmaceuticals Inc. | $405.2M | -5.7x | -3.2x | -33.7% | N/A | N/A | N/A | N/A | N/A |
| DNA | Ginkgo Bioworks Holdings Inc. | $402.4M | -1.5x | -1.3x | -0.1% | 17.3% | -105.0% | N/A | N/A | N/A |
Financial Charts
No financial data available for NUVB (annual).
2 superinvestors own NUVB
Current quarter ownership and quarter-over-quarter share changes.
Superinvestor ownership
| Fund | Shares | Value | % Portfolio | QoQ Change |
|---|---|---|---|---|
| David Abrams Abrams Capital Management | 1,270,504 | $5M | 0.12% | 0.0% |
| David Einhorn Greenlight Capital | 34,995 | $150,000 | 0.00% | 0.0% |